EUVIMEDEUVIMED entdecken
Editorial

Glucagon‐like peptide‐1 agonists for treating substance use disorders: ready for clinical use?

Grace Meulman, Alicia Foran, Darren M Roberts

Internal Medicine Journal · 2026-05 · 56 (5) · 745-749

DOI: 10.1111/imj.70458 ↗

Kurz gefasst

Editorial in der Zeitschrift Internal Medicine Journal, online erschienen am 13.05.2026. Verfasst von Grace Meulman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Edith Collins Centre, Drug Health Services, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. Die Arbeit nennt 36 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Edith Collins Centre, Drug Health Services, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • School of Clinical Medicine, University of New South Wales, Sydney, New South Wales, Australia.

Zitieren

APA

Meulman, G., Foran, A., & Roberts, D. M. (2026). Glucagon‐like peptide‐1 agonists for treating substance use disorders: ready for clinical use?. Internal Medicine Journal, 56(5), 745-749. https://doi.org/10.1111/imj.70458

Vancouver

Meulman G, Foran A, Roberts DM. Glucagon‐like peptide‐1 agonists for treating substance use disorders: ready for clinical use?. Internal Medicine Journal. 2026;56(5):745-749. doi:10.1111/imj.70458

BibTeX
@article{Meulman2026,
  author = {Meulman, Grace and Foran, Alicia and Roberts, Darren M},
  title = {Glucagon‐like peptide‐1 agonists for treating substance use disorders: ready for clinical use?},
  journal = {Internal Medicine Journal},
  year = {2026},
  volume = {56},
  number = {5},
  pages = {745--749},
  doi = {10.1111/imj.70458}
}
Kostenlos starten →